ARAY

Business Context and Reporting Period

Company: Accuray Incorporated (ARAY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended June 30, 2025
Business Overview: Accuray develops and manufactures radiation therapy systems, primarily the CyberKnife (robotic radiosurgery) and TomoTherapy (helical radiation therapy) platforms, along with associated software and services. The company operates globally with significant manufacturing in the U.S. and China, and a joint venture (JV) in China to manufacture and sell systems locally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 3% year-over-year, driven by a 20% increase in China revenue and a 65% increase in Asia Pacific revenue, partially offset by a 14% decline in EIMEA (Europe, India, Middle East, Africa) due to geopolitical disruptions.
• Profitability Improvement: Operating income improved significantly from $0.5 million to $7.8 million, and the net loss narrowed substantially from $15.5 million to $1.6 million.
• Debt Restructuring: In June 2025, the company entered a new $150 million Term Loan Facility and refinanced prior debt. It also exchanged approximately $82 million of Convertible Notes for cash and common stock, leaving $18 million of Convertible Notes outstanding.
• Order Backlog: Net orders decreased by $33.7 million to $177.2 million, primarily due to lower gross orders in the Americas. The book-to-bill ratio declined to 1.2 from 1.5.
• Equity Method Investment: Income from the China Joint Venture increased 156% to $4.7 million, reflecting higher JV revenues.

Guidance, Outlook, and Risks

• Outlook: Management expects inflation, supply chain challenges, and logistics costs to continue adversely affecting gross margins and cash flow through at least calendar year 2025. Reduced budgets and longer installation timelines in the U.S. are expected to impact net revenue through fiscal year 2026.
• Tariff Risks: Significant uncertainty remains regarding U.S.-China trade tariffs. The company expects sales to China to be adversely impacted and costs to increase through the first half of fiscal 2026.
• Liquidity: The company believes current cash and debt facilities are sufficient to fund operations for at least the next 12 months. However, compliance with financial covenants (fixed charge coverage, leverage ratio) depends on future operating performance.
• Internal Controls: Material weaknesses in internal controls identified in the prior year (related to manual journal entries and inventory existence) were remediated as of March 31, 2025. The company now reports effective internal controls as of June 30, 2025.
• Unusual Items: The company recorded a $1.5 million gain on the extinguishment of debt and a $0.5 million loss on the change in fair value of warrant liabilities.

Key Facts for Investor Verification

• Debt Covenants: Verify the company's ability to maintain compliance with the new Financing Agreement's financial covenants (leverage ratio, fixed charge coverage, minimum liquidity) given the macroeconomic headwinds.
• China Exposure: Assess the impact of U.S.-China tariffs and the performance of the China Joint Venture, which accounts for 27% of total net revenue.
• Backlog Conversion: Monitor the conversion rate of the $427 million order backlog into revenue, noting the risk of cancellations and age-outs (orders not recognized within 30 months).
• Single-Source Suppliers: Review reliance on single-source suppliers for critical components (robot, couch, magnetron) and the potential for supply chain disruptions to impact delivery timelines.
• Convertible Notes: Track the remaining $18 million of Convertible Notes due June 1, 2026, and the company's plan to repay them using operating cash or the Delayed Draw Facility.